Pretending to be positive, while both supporting and sequentially ignoring, the causes of major global economic cumulative effects is NOT a solution.
- Only two things left to tax or require purchase of: air for breathing, and a “continued right to life” license tax. Otherwise, everything else required for LIFE is now available by purchase only, taxation applied.
The Treasury prints and mints all paper currency and coins in circulation through the Bureau of Engraving and Printing and the United States Mint. The Department also collects allfederal taxes through the Internal Revenue Service, and manages U.S. government debt instruments.
TAX & INSURANCE DOLLARS: The new 21st century’s, now Unlimited, Gold Mine
- Has opened the doors to PROFIT unlimited, creating
- Colossal, gargantuan, humongous, behemoth, stupendous, towering entities serving the needs of humankind……. Oops, sorry, serving the needs of their shareholders, first and foremost.
CARING ABOUT LIFE AND PROFIT– a look at the pharmaceutical, medical, health care, and related insurance industry sectors. The meaning, definition, has merged completely, with no distinction between LIFE and PROFIT.
Corporate Town Hall Meetings: We are doing everything we can, BUT YOUR INSURANCE PREMIUMS AND YOUR MEDICAL COSTS WILL CONTINUE TO RISE and ACCELERATE UPWARDS. It is just the way it is (????)
Mirror, Mirror on the Wall, 2014 Update: How the U.S. Health Care System Compares Internationally U.S. ranks last, as it did in the 2010, 2007, 2006, and 2004.
The United States health care system is the most expensive in the world, but this report and prior editions consistently show the U.S. underperforms relative to other countries on most dimensions of performance. Among the 11 nations studied in this report—Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, and the United States—the U.S. ranks last, as it did in the 2010, 2007, 2006, and 2004 editions of Mirror, Mirror. Most troubling, the U.S. fails to achieve better health outcomes than the other countries, and as shown in the earlier editions, the U.S. is last or near last on dimensions of access, efficiency, and equity.
Questcor Finds Profits, at $28,000 a Vial December 29, 2012 The doctor was dumbfounded: a drug that used to cost $50 was now selling for $28,000 for a 5-milliliter vial.
BECAUSE WE CAN (AND THE CROWD SCREAMS ‘MORE, MORE, MORE!!!’)
Rx R&D Myths: The Case Against The Drug Industry’s R&D “Scare Card”
- Drug Industry R&D costs are significantly reduced by taxpayer-funded research subsidies
- Significant expenses in the Drug Industry are tax deductible
- Drug industry’s effective tax rate is about 40 percent less than the average for all other industries
Medicine, Pills, Still Exploding Exponentially – Skyrocketing Health-Care Premiums
Health-Insurance Rates Are Rapidly Increasing, With No End in Sight – By Jackie Judd April 25, 2002 — Jon Ward was stunned when a health-insurance agent told him his company’s premiums were going up 48 percent this spring.
The drug industry claims its high profits are necessary in order to conduct expensive research and development. It spends more on research than any other industry. The federally funded National Institutes of Health may be the drug industry’s biggest benefactor. This government agency alone will spend more than $23 billion on research this year. And much of the research benefits the drug industry. “There’s no other industry in which you have so much public investment in the fundamental knowledge that enables … the development of the commercial industry itself,” said Dr. Bernadine Healy, who used to run the NIH. And how important is this publicly funded research to the industry? The NIH looked at the five top-selling drugs of 1995 in a report. It found that “NIH-funded research played a critical role” in discovering each one of those drugs. Similar to Existing Drugs A closer look reveals that much of the profits from prescription sales are not derived from breakthrough drugs, but rather from drugs that are similar to already popular medications. But, adding up all the drugs approved over the past six years, 80 percent of all those drugs were deemed by the FDA to be similar to what already exists. In other words, not a significant improvement.